Learn
In the Media
Laboratory Focus: InMed and UBC Receive Grant From NSERC
InMed Pharmaceuticals Inc., announces that their research partner, the University of British Columbia (UBC), has been approved to receive a grant from the Natural Sciences and Engineering...
Source: Laboratory Focus
InMed Files Patent Application for its Cannabinoid Biosynthesis Program
InMed Pharmaceuticals Inc. (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of...
Source: City Biz List
Are cannabinoids the new wave for treating human diseases?
While many of the stigmas and steadfast opinions against marijuana use have begun to dissolve, the U.S. government still currently classifies marijuana as a Schedule 1...
Source: Healthcare Global
BTV: InMed Pharmaceuticals Specializes in Developing Cannabinoid-based Therapeutics
InMed Pharmaceuticals specializes in developing cannabinoid-based therapeutics to treat serious diseases with high unmet medical needs.
Source: BTV